This iatrogenic condition results from overstimulation of the ovaries in the course of infertility treatment. It most commonly is associated with gonadotrophin therapy.
Women at risk of ovarian hyperstimulation syndrome (OHSS) are generally young and have polycystic ovary syndrome (PCOS) (1).
OHSS is characterised by enlarged ovaries and an acute fluid shift from the intravascular space to the third space (mainly to the abdominal or thoracic cavity), which may result in an accumulation of fluid in the peritoneal cavity and pleura, an elevation of haematocrit, and a decrease in organ perfusion.
Mild hyperstimulation occurs in up to 10% of patients receiving hMG. Ovarian enlargement and cyst formation produces abdominal discomfort, swelling and pain. Rest and simple analgesia for example, aspirin provides relief.
Moderate or severe OHSS arises in 3% to 8% of IVF cycles (2)
Moderate hyperstimulation is indicated by nausea, vomiting, diarrhoea, abdominal discomfort and often, some weight gain. Treatment is as for mild hyperstimulation but patients should be closely monitored in case symptoms worsen.
Severe hyperstimulation occurs in about 1% of patients. There may be ascites and pleural effusion. Changes in blood clotting may result in thrombosis. Hospitilisation is required with correction of fluid abnormalities.
Prevention requires careful monitoring - ultrasound to assess the number and size of the follicles, and testing of serum oestrogen levels.
There is evidence that dopamine agonists probably reduce the incidence of moderate or severe OHSS compared to placebo/no intervention (3)
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.